Literature DB >> 8341138

SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity.

R Albert1, P Marbach, W Bauer, U Briner, G Fricker, C Bruns, J Pless.   

Abstract

To obtain orally active octreotide (Sandostatin, SMS 201-995) analogs a new class of glycated somatostatin derivatives were synthesized by the Amadori reaction (Maillard reaction). The synthesis, chemical and biological characterization of a series of new compounds is described. These oligopeptides bind with high affinity to somatostatin receptors and retain full biological activity. Whereas generally polypeptide hormones are almost completely inactive after oral administration, we report here for the first time that these analogs show remarkably high activity by the oral route. Thus for example SDZ CO 611, the D(+)-maltose Amadori derivative of octreotide, has about 10 times higher oral effect bioavailability than octreotide while maintaining the selectivity, metabolic stability and long duration of action of the parent compound.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341138     DOI: 10.1016/0024-3205(93)90703-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

1.  Highly Selective β-Mannosylations and β-Rhamnosylations Catalyzed by Bis-thiourea.

Authors:  Qiuhan Li; Samuel M Levi; Eric N Jacobsen
Journal:  J Am Chem Soc       Date:  2020-06-26       Impact factor: 15.419

Review 2.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 3.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

4.  Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats.

Authors:  C Chen; G M Pollack
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

Review 5.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

6.  Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Josef Vagner; Vinod Kulkarni; Peg Davis; Shou-Wu Ma; Edita Navratilova; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

7.  Glycans Meet Sphingolipids: Structure-Based Design of Glycan Containing Analogues of a Sphingosine Kinase Inhibitor.

Authors:  Athanasios Papakyriakou; Francesca Cencetti; Elisa Puliti; Laura Morelli; Jacopo Tricomi; Paola Bruni; Federica Compostella; Barbara Richichi
Journal:  ACS Med Chem Lett       Date:  2020-03-30       Impact factor: 4.345

Review 8.  Glycopeptide drugs: A pharmacological dimension between "Small Molecules" and "Biologics".

Authors:  Christopher R Apostol; Meredith Hay; Robin Polt
Journal:  Peptides       Date:  2020-07-13       Impact factor: 3.750

9.  A drug delivery strategy: binding enkephalin to asialoglycoprotein receptor by enzymatic galactosylation.

Authors:  Michelle P Christie; Pavla Simerská; Freda E-C Jen; Waleed M Hussein; Mohamad F M Rawi; Lauren E Hartley-Tassell; Christopher J Day; Michael P Jennings; Istvan Toth
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

Review 10.  Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain.

Authors:  Pegah Varamini; Istvan Toth
Journal:  Front Pharmacol       Date:  2013-12-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.